Magnetic resonance imaging of the pancreas and pancreatic tumors in a mouse orthotopic model of human cancer

International Journal of Cancer

Volumn 106, Issue 5, 2003, Pages 806-811

  Grimm, Jan ^a,d   Potthast, Andreas ^b   Wunder, Andreas ^a,c   Moore, Anna ^a,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e NONE   (United States)

Author keywords

MRI; Pancreas; Tumor model

Indexed keywords

GADOLINIUM PENTETATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER SIZE; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SCID MOUSE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MICE; MICE, SCID; PANCREAS; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0041522419     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11281     Document Type: Article

References (27)

1. Silverberg E, Lubera JA. Cancer statistics, 1989. CA Cancer J Clin 1989;39:3-20.
2. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
3. Gordis L, Gold EB. Epidemiology of pancreatic cancer. World J Surg 1984;8:808-21.
4. Hakulinen T, Andersen A, Malker B, Pukkala E, Schou G, Tulinius H. Trends in cancer incidence in the Nordic countries. A collaborative study of the five Nordic Cancer Registries. Acta Pathol Microbiol Immunol Scand Suppl 1986;288:1-151.
5. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909.
6. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987;60:2284-303.
7. Cardillo TM, Blumenthal R, Ying Z, Gold DV. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int J Cancer 2002;97:386-92.
8. Lopez Hanninen E, Amthauer H, Hosten N, Ricke J, Bohmig M, Langrehr J, Hintze R, Neuhaus P, Wiedenmann B, Rosewicz S, Felix R. Prospective evaluation of pancreatic tumors: accuracy of MR imaging with MR cholangiopancreatography and MR angiography. Radiology 2002;224:34-41.
9. Reinhold C. Magnetic resonance imaging of the pancreas in 2001. J Gastrointest Surg 2002;6:133-5.
10. Robinson PA. The role of MRI in pancreatic cancer. Eur Radiol 2002;12:267-9.
11. Oudkerk M, Torres CG, Song B, Konig M, Grimm J, Fernandez-Cuadrado J, Op de Beeck B, Marquardt M, van Dijk P, de Groot JC. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT. Radiology 2002;223:517-24.
12. Grimm J, Muller-Hulsbeck S, Blume J, Biederer J, Heller M. [Comparison of biphasic spiral CT and MnDPDP-enhanced MRI to detect and classify liver lesions]. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2001;173:266-72.
13. Eskelinen MJ, Haglund UH. Prognosis of human pancreatic adenocarcinoma: review of clinical and histopathological variables and possible uses of new molecular methods. Eur J Surg 1999;165:292-306.
14. Cui JH, Kruger U, Vogel I, Luttges J, Henne-Bruns D, Kremer B, Kalthoff H. Intact tissue of gastrointestinal cancer specimen orthotopically transplanted into nude mice. Hepatogastroenterology 1998; 45:2087-96.
15. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes Memorial Award lecture. Cancer Res 1990;50:6130-8.
16. Tan MH, Chu TM. Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPC-1) implanted orthotopically into nude mice. Tumour Biol 1985;6:89-98.
17. Juhl H, Sievers M, Baltzer K, Helmig F, Wolf H, Brenner W, Kalthoff H. A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach. Cancer Res 1995;55(23 Suppl):5749s-55s.
18. He Z, Evelhoch JL, Mohammad RM, Adsay NV, Pettit GR, Vaitkevicius VK, Sarkar FH. Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer. Pancreas 2000;21:69-76.
19. Moore A, Bonner-Weir S, Weissleder R. Noninvasive in vivo measurement of beta-cell mass in mouse model of diabetes. Diabetes 2001;50:2231-6.
20. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001;219: 316-33.
21. Kobayashi H, Kawamoto S, Jo SK, Sato N, Saga T, Hiraga A, Konishi J, Hu S, Togashi K, Brechbiel WM, Star RA. Renal tubular damage detected by dynamic micro-MRI with a dendrimer-based magnetic resonance contrast agent. Kidney Int 2002;61:1980-5.
22. Herborn CU, Waldschuetz R, Lauenstein TC, Goyen M, Lauffer RB, Moeroey T, Debatin JF, Ruehm SG. Contrast-enhanced magnetic resonance imaging (MS-325) in a murine model of systemic lupus erythematosus. Invest Radiol 2002;37:464-9.
23. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, Basilion JP. In vivo magnetic resonance imaging of transgene expression. Nat Med 2000;6:351-5.
24. Szepeshazi K, Schally AV, Halmos G, Sun B, Hebert F, Csernus B, Nagy A. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. Clin Cancer Res 2001;7:2854-61.
25. Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer 1994;57:568-73.
26. Seki Y, Naruse S, Seo Y, Kitagawa M, Ishiguro H, Wang Y, Murakami M, Hayakawa T. Time-course magnetic resonance imaging of rat pancreatic cyst after experimental pancreatitis. Magn Reson Imaging 2000;18:1003-10.
27. Moore A, Grimm J, Josephson L, Weissleder R, Santamaria H. Noninvasive imaging of insulitis lesions in the mouse model of type 1 diabetes. Mol Imaging 2002;1:236.